91 related articles for article (PubMed ID: 10098751)
21. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study.
Punjabi S; Cook LJ; Kersey P; Marks R; Cerio R
Int J Dermatol; 2008 Jan; 47(1):78-82. PubMed ID: 18173610
[TBL] [Abstract][Full Text] [Related]
22. First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer.
Fiorentini G; Tsetis D; Bernardeschi P; Varveris C; Rossi S; Kalogeraki A; Athanasakis E; Dentico P; Kanellos P; Biancalani M; Almarashdah S; Zacharioudakis G; Saridaki Z; Chalkiadakis G; Xynos E; Zoras O
Anticancer Res; 2003; 23(5b):4339-45. PubMed ID: 14666649
[TBL] [Abstract][Full Text] [Related]
23. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
24. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Acta Oncol; 2005; 44(7):773-7. PubMed ID: 16227173
[No Abstract] [Full Text] [Related]
25. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
30. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
Eichbaum MH; Schuetz F; Khbeis T; Lauschner I; Foerster F; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Sep; 18(8):963-8. PubMed ID: 17667603
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
32. Miltefosine in recurrent cutaneous breast cancer.
Clive S; Leonard RC
Lancet; 1997 Mar; 349(9052):621-2. PubMed ID: 9057742
[No Abstract] [Full Text] [Related]
33. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Sindermann H; Peukert M; Hilgard P; Engel J; Eibl H
Prog Exp Tumor Res; 1992; 34():153-9. PubMed ID: 1438798
[No Abstract] [Full Text] [Related]
34. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Planting AS; Stoter G; Verweij J
Eur J Cancer; 1993; 29A(4):518-9. PubMed ID: 8435202
[TBL] [Abstract][Full Text] [Related]
35. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
36. [Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
Viseux V; Schoenlaub P; Danhier S; Vilque JP; Plantin P
Ann Dermatol Venereol; 2004 Feb; 131(2):204-5. PubMed ID: 15026752
[No Abstract] [Full Text] [Related]
37. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.
Dummer R; Krasovec M; Röger J; Sindermann H; Burg G
J Am Acad Dermatol; 1993 Dec; 29(6):963-70. PubMed ID: 8245262
[TBL] [Abstract][Full Text] [Related]
38. Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Unger C; Eibl H; Breiser A; von Heyden HW; Engel J; Hilgard P; Sindermann H; Peukert M; Nagel GA
Onkologie; 1988 Dec; 11(6):295-6. PubMed ID: 3071766
[No Abstract] [Full Text] [Related]
39. Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience.
Bourke MG; Salwa SP; Sadadcharam M; Whelan MC; Forde PF; Larkin JO; Collins CG; O'Reilly S; O'Sullivan GC; Clover AJ; Soden DM
Breast Cancer Res Treat; 2017 Jan; 161(2):289-297. PubMed ID: 27878392
[TBL] [Abstract][Full Text] [Related]
40. [Ultrastructural changes in breast cancer metastases following intralesional injections of MER].
Bar-Sella P; Nir I; Bartal A; Robinson E
Harefuah; 1980 Dec; 99(12):413-5. PubMed ID: 7250842
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
